MarketCap
Facebook
X
TelegramAnnual report 2023
added 03-27-2024
Ampio Pharmaceuticals ROE Ratio 2011-2026 | AMPE
Annual ROE Ratio Ampio Pharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -256.9 | -138.58 | -62.58 | -90.76 | -211.55 | 649.07 | 151.83 | -288.86 | -84.4 | -58.24 | -72.28 | -48.65 | -103.38 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 649.07 | -288.86 | -47.33 |
Quarterly ROE Ratio Ampio Pharmaceuticals
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -140.55 | -163.98 | -153.38 | -81.92 | -102.94 | -77.68 | -84.86 | -60.39 | -79.62 | -77.83 | -75.94 | -64.4 | -176.45 | -269.26 | -247.13 | -195.72 | -84.92 | 137.91 | 219.62 | 619.94 | 746.13 | 647.78 | 567.18 | 108.18 | -68.57 | -121.86 | -167.93 | -167.6 | -144.08 | -122.57 | -104.01 | -85.95 | -73.9 | -68.59 | -61.86 | -57.66 | -64.86 | -69.18 | -75.44 | -134.11 | -127.35 | -157.64 | -186.88 | -161.38 | -249.32 | -304.05 | -358.77 | -256.18 | -103.38 | -103.38 | -49.43 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 746.13 | -358.77 | -53.65 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Autolus Therapeutics plc
AUTL
|
-51.64 | $ 1.96 | -2.25 % | $ 500 M |  Britain |
 |
AgeX Therapeutics
AGE
|
-270.67 | - | -10.17 % | $ 12.2 K |  USA |
 |
MorphoSys AG
MOR
|
15.76 | - | 2.43 % | $ 254 M |  Germany |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
114.5 | $ 11.68 | 21.41 % | $ 755 M | USA |
 |
AlloVir
ALVR
|
-51.87 | - | 4.14 % | $ 49.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.18 | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
-751.94 | - | -13.47 % | $ 169 M |  France |
 |
Aeglea BioTherapeutics
AGLE
|
-40.17 | - | - | $ 1.01 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-115.61 | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
-330.29 | - | -18.52 % | $ 27.3 M | Britain |
 |
Can-Fite BioPharma Ltd.
CANF
|
-144.96 | $ 4.79 | 20.35 % | $ 10.4 B |  Israel |
 |
CASI Pharmaceuticals
CASI
|
-43.38 | $ 0.83 | -2.51 % | $ 113 M | USA |
 |
Ascendis Pharma A/S
ASND
|
-43.41 | $ 212.47 | 1.52 % | $ 5 B |  Danmark |
 |
Aclaris Therapeutics
ACRS
|
-84.9 | $ 2.68 | 0.94 % | $ 207 M | USA |
 |
AIkido Pharma
AIKI
|
-36.89 | - | 1.93 % | $ 17.4 M | USA |
 |
Albireo Pharma
ALBO
|
-19.38 | - | -0.23 % | $ 916 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
17.55 | - | - | - |  Russia |
 |
Alpine Immune Sciences
ALPN
|
-32.19 | - | - | $ 2.17 B | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
20.78 | $ 37.22 | 4.17 % | $ 3.84 B | USA |
 |
ARCA biopharma
ABIO
|
-21.9 | - | 1052.0 % | $ 415 M | USA |
 |
Applied Molecular Transport
AMTI
|
-207.64 | - | - | $ 10.1 M | USA |
 |
Acasti Pharma
ACST
|
-14.36 | - | 4.01 % | $ 150 M |  Canada |
 |
Catalyst Pharmaceuticals
CPRX
|
22.52 | $ 22.74 | 0.71 % | $ 2.69 B | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
-288.19 | - | -15.15 % | $ 60.3 M | Britain |
 |
Athersys
ATHX
|
-531.22 | - | 3.77 % | $ 22.4 M | USA |
 |
BioNTech SE
BNTX
|
1.11 | $ 100.27 | 2.22 % | $ 27.2 B | Germany |
 |
CorMedix
CRMD
|
-66.06 | $ 11.22 | -0.36 % | $ 571 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
21.78 | $ 27.37 | -0.92 % | $ 1.33 B | USA |
 |
Avenue Therapeutics
ATXI
|
-418.16 | - | -52.27 % | $ 4.45 M | USA |
 |
CureVac N.V.
CVAC
|
-59.8 | $ 4.66 | - | $ 867 M | Germany |
 |
AVROBIO
AVRO
|
12.83 | - | 1083.1 % | $ 745 M | USA |
 |
BioDelivery Sciences International
BDSI
|
45.18 | - | -4.8 % | $ 255 M | USA |
 |
Catalyst Biosciences
CBIO
|
540.06 | $ 10.96 | -0.99 % | $ 722 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
-91.56 | - | -6.81 % | $ 3.04 B | USA |
 |
BeiGene, Ltd.
BGNE
|
-19.35 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Acer Therapeutics
ACER
|
156.54 | - | 2.71 % | $ 14 M | USA |
 |
BioVie
BIVI
|
-92.27 | $ 1.37 | -1.26 % | $ 2.02 M | USA |
 |
Axon Enterprise
AXON
|
16.2 | $ 620.25 | -1.02 % | $ 47 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
3458.87 | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
-71.51 | $ 2.84 | 4.41 % | $ 17.8 M | USA |
 |
AstraZeneca PLC
AZN
|
20.44 | $ 94.86 | -0.11 % | $ 96.9 B | Britain |
 |
Cellectis S.A.
CLLS
|
-26.25 | $ 4.55 | 3.06 % | $ 116 M | France |
 |
Bellicum Pharmaceuticals
BLCM
|
-1239.35 | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
-69.02 | - | -7.31 % | $ 87 M | USA |
 |
Acorda Therapeutics
ACOR
|
160.08 | - | -24.86 % | $ 820 K | USA |
 |
Brickell Biotech
BBI
|
-57.34 | - | -5.38 % | $ 6.06 M | USA |
 |
Burford Capital Limited
BUR
|
10.1 | $ 9.32 | 0.27 % | $ 1.51 B | Britain |
 |
bluebird bio
BLUE
|
-108.93 | - | - | $ 546 M | USA |
 |
Biogen
BIIB
|
9.76 | $ 184.12 | 0.83 % | $ 26.8 B | USA |